ArticleClinical and experimental medicine2025
Identification and external validation of a prognostic signature based on MAPK-related genes to evaluate survival prognosis and treatment efficacy in lung adenocarcinoma.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pan-cancer analysis of OSR2 with a focus on underlying mechanisms and therapeutic implications in lung adenocarcinoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe mitogen-activated protein kinase (MAPK) pathway plays a pivotal role in tumorigenesis and immune regulation. However, its prognostic significance in lung adenocarcinoma (LUAD) remains poorly defined. This study aimed to construct a robust MAPK-related gene (MRG) signature by integrating multi-omics data to enhance risk stratification and therapeutic guidance in LUAD.
methodsDifferentially expressed MRGs were identified from TCGA-LUAD transcriptomic data and prioritized through Mendelian randomization (MR) analysis. A prognostic model was constructed using the random survival forest (RSF) algorithm and validated across three independent Gene Expression Omnibus (GEO) cohorts. Additional analyses were developed including pathway enrichment, drug sensitivity prediction, reverse transcription quantitative PCR (RT-qPCR) validation, and single-cell RNA sequencing (scRNA-seq) to uncover its mechanistic basis and clinical value.
resultsThe MRG-based model effectively stratified patients into high-risk (HRG) and low-risk groups (LRG) with significant differences in overall survival (P < 0.001). The nomogram-derived risk score outperformed clinical factors in predicting outcomes, reflecting strong prognostic capability of the model. HRG exhibited elevated tumor mutational burden (TMB), enrichment of PI3K-Akt signaling, both of which may be associated with its poorer prognosis. Drug sensitivity profiling suggested that LRGs were more responsive to PI3K/mTOR inhibitors, whereas HRGs favored tyrosine kinase inhibitors. scRNA-seq analysis revealed that MRGs were mainly enriched in endothelial cell populations, implicating their role in immune modulation and angiogenesis.
conclusionsThis integrative multi-omics-based prognostic model provides robust predictive power and novel biological insights, serving as a practical tool for personalized prognosis evaluation and targeted therapeutic decision-making in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.